Abstract
Nitric oxide synthase (NOS) may be uncoupled to produce superoxide rather than nitric oxide (NO) under pathological conditions such as diabetes mellitus and insulin resistance, leading to cardiac contractile anomalies. Nonetheless, the role of NOS uncoupling in insulin resistance-induced cardiac dysfunction remains elusive. Given that folic acid may produce beneficial effect for cardiac insufficiency partially through its NOS recoupling capacity, this study was designed to evaluate the effect of folic acid on insulin resistance-induced cardiac contractile dysfunction in a sucrose-induced insulin resistance model. Mice were fed a sucrose or starch diet for 8 weeks prior to administration of folic acid in drinking water for an additional 4 weeks. Cardiomyocyte contractile and Ca2+ transient properties were evaluated while myocardial function was assessed using echocardiography. Our results revealed whole body insulin resistance following sucrose feeding associated with diminished NO production, elevated peroxynitrite (ONOO−) levels, as well as impaired echocardiographic and cardiomyocyte function along with a leaky ryanodine receptor (RYR) and intracellular Ca2+ handling derangement. Western blot analysis depicted that insulin resistance significantly promoted Ca2+/Calmodulin-dependent protein kinase II (CaMKII) phosphorylation which might be responsible for the leaky RYR and cardiac mechanical dysfunction. NOS recoupling using folic acid reversed insulin resistance-induced changes in NO and ONOO−, CaMKII phosphorylation and cardiac mechanical abnormalities. Taken together, these data demonstrated that treatment with folic acid may reverse cardiac contractile and intracellular Ca2+ anomalies through ablation of CaMKII phosphorylation and RYR Ca2+ leak.
Keywords: Insulin resistance, folic acid, cardiac function, intracellular Ca2+, CaMKII
INTRODUCTION
Type 2 diabetes mellitus is a significant health problem in the United States and continues to rise with the prevalence of obesity. Cardiovascular diseases are the leading cause of death among diabetic individuals but available treatments are limited to symptom control of cardiovascular problems [1]. One of the early indicators of diabetes development is impaired ability to respond to insulin, termed insulin resistance. During insulin resistance prior to the onset of diabetes, the accumulation of reactive oxygen species (ROS) can be seen in hearts [2], which contributes to cardiac dysfunction through peroxidation of lipids and proteins, extracellular matrix remodeling, mitochondrial damage, and alteration in the excitation contraction coupling proteins [3]. Several sources of ROS have been identified in the heart under insulin resistance including nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, xanthine oxidase, mitochondria, and uncoupled nitric oxide synthase (NOS) [3]. Recent evidence has depicted a pivotal pathological role of uncoupled NOS as a primary source in the heart while drug therapy targeting this enzyme has shown some promises in the management of heart diseases [4–6].
Folic acid has been shown to exhibit beneficial effects in a wide array of heart diseases. During ischemia reperfusion, high dose folic acid may prevent myocardial dysfunction, preserve high energy phosphate, abrogate ROS generation and eNOS uncoupling [7]. In the vasculature, folic acid treatment may reduce abdominal aortic aneurysm formation and prevent eNOS uncoupling, which may be associated with its stimulatory effect on dihydrofolate reductase [8, 9]. Hyperhomocysteinemia is an important independent risk factor for cardiovascular diseases. It has been suggested that the detrimental effect of homocysteine can be alleviated by folic acid administration with a concurrent reduction of superoxide generation [10, 11]. Previous evidence has implicated the therapeutic potential of folic acid in cardiovascular disorders in particular NOS uncoupling [12] although the impact of folic acid on insulin resistance-induced cardiac complication still remains elusive.
Excitation-contraction coupling in the heart involves three types of Ca2+ channel in particular L-type Ca2+ channel, ryanodine receptor (RYR), Na+-Ca2+ exchanger and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) [13]. Among which, RYR is responsible for Ca2+-induced Ca2+ release to initiate myocardial contraction. RYR is susceptible to posttranslational modification by oxidation or phosphorylation leading to Ca2+ leak en route to onset and development of arrhythmic and myopathic alterations [14]. A number of signaling machineries have been put forward for the regulation of RYR. Ca2+/Calmodulin-dependent protein kinase II (CaMKII) is a protein the activation of which leads to phosphorylation of RYR, subsequently Ca2+ leak and contractile aberration [15]. Although a detrimental role of CaMKII phosphorylation has been reported is identified in diabetes [16], little is known for CaMKII phosphorylation in the setting of insulin resistance. To this end, the aim of this study was to evaluate if cardiac dysfunction in the setting of insulin resistance induced by a high sucrose diet may be reversed with folic acid. In an effort to understand the mechanism behind folic acid-induced response in insulin resistance, a number of cell mechanisms were evaluated in sucrose-fed mouse hearts treated with or with folic acid including NOS uncoupling, levels of NO and peroxynitrite (ONOO−), a reactive product of NO and superoxide anion (O2−) [17], RYR function, CaMKII phosphorylation and intracellular Ca2+ regulatory proteins.
MATERIALS AND METHODS
Experimental animals, intraperitoneal glucose tolerance test (IPGTT) and echocardiographic analysis
Experimental procedures used in this study were approved by the University of Wyoming Institutional Animal Use and Care Committee (Laramie, WY). Insulin resistance was induced in Friend Virus B (FVB) mice as previously described [18]. Briefly, 3 month-old adult FVB mice were randomly divided into two groups to receive either a high starch diet (68% of energy from starch, Research Diets, D11724, New Brunswick, NJ) or a high sucrose diet (68% of energy from sucrose, Research Diets, D11725). After 8 weeks of starch and sucrose feeding, cohorts of mice received folic acid (15 mg/kg/day) or vehicle in drinking water for an additional 4 weeks [8, 9]. Water consumption was monitored to ensure equal dose for all 4 groups. On the last day (23:00 hour) of folic acid treatment, food was removed and all mice were fasted for 12 hours overnight prior to IPGTT the next day [18]. After obtaining a baseline glucose reading, mice were challenged with glucose (2 g/kg, i.p.) and glucose measurements were taken 15, 30, 60 and 120 min after injection. Glucose concentration was assessed using an ACCU-CHEK advantage glucose analyzer (Roche Diagnostics, Indianapolis, IN). Mice were then provided respective starch or sucrose diet following IPGTT with regular drinking water. Cardiac function was assessed the next morning (08:00 hour) using 2-D guided M-mode echocardiography (Sonos 5500) equipped with a 15-6 MHz linear transducer (Phillips Medical Systems, Andover, MD) in anesthetized (Avertin 2.5%, 10 µl/g, i.p.) mice. Fractional shortening was calculated from left ventricular end-diastolic diameter (LVEDD) and left ventricular end-systolic diameter (LVESD) using the following equation (LVEDD-LVESD)/LVEDD. Thirty-six hrs following completion of folic acid treatment (11:00 hour on the next day following echocardiographic assessment), mice were anesthetized with ketamine (80 mg/kg, i.p.) and xylazine (12 mg/kg, i.p.) and sacrificed using cardioectomy to collect heart tissues.
Cardiomyocyte isolation and cell mechanics
Hearts were removed rapidly from mice sedated with ketamine (80 mg/kg, i.p.) and xylazine (12 mg/kg, i.p.) and perfused with Krebs-Henseleit bicarbonate solution consisting of (in mM) 118 NaCl, 4.7KCl, 1.2 MgSO4, 1.2 KH2PO4, 25 NaHCO3, 10 HEPES and 11.1 glucose. Hearts were digested with Liberase Blendzyme 4 (Roche Diagnostics) for 15 min. After removal and mincing of left ventricle, Ca2+ was added back to a final concentration of 1.25 mM. Cardiomyocytes with no spontaneous contractions and clear edges were used for shortening and Ca2+ cycling experiments. IonOptix™ softedge system (IonOptix, Milton MA) was used to assess the mechanical properties of isolated myocytes. Myocytes were mounted on the stage of an Olympus IX-70 microscope in contraction buffer containing (in mM) 131 NaCl, 4 KCl, 1CaCl2, 1 MgCl2, 10 glucose and 10 HEPES. Myocytes were stimulated at 0.5 Hz with cell shortening and relengthening evaluated using the indices: peak shortening (PS), time to peak shortening (TPS), time to 90% relengthening (TR90) and maximal velocities of shortening/relengthening (± dL/dt).
Intracellular Ca2+ transient, RYR leak and spontaneous contractions
Myocytes were loaded with fura-2/AM (0.5 µM) for 10 min. After washing with contraction buffer (recipe above), fluorescence intensity was recorded with a dual excitation fluorescence photomultiplier system (IonOptix). Myocytes were stimulated at 0.5 Hz and excited at 360 and 380nm with fluorescence emissions detected at 480 and 520 nm, respectively. Intracellular Ca2+ levels were calculated using the ratio of the two wavelengths (360/380). Leak from ryanodine receptor was assessed as previously described with minor modification [19, 20]. Myocytes loaded with fura 2/AM were incubated with 0Na+ OCa2+ buffer containing (in mM) 140 LiCl, 4 KCl, 1 MgCl, 10 glucose, and 5 HEPES with the pH adjusted to 7.4 using LiOH. Myocytes in 0Na+ 0Ca2+ buffer were mounted on the microscope and intracellular Ca2+ levels were assessed for 80 seconds without field stimulation. 0Na+-0Ca2+ buffer with tetracaine (1 mM) was added and resting Ca2+ levels were assessed again. RYR leak was calculated using the area between resting curve and tetracaine curve, [(0Na+-0Ca2+ AUC) − (0Na+-0Ca2+ + tetracaine AUC)]. An Ionwizard analysis software (IonOptix) was used to perform the calculation.
Superoxide anion production and NOS uncoupling
Superoxide production was assessed as described [20]. In brief, 30 µm tissue sections were cut from fresh unfixed heart sections frozen in O.C.T. (Tissue-Tek, Torrence, CA). Sections were incubated with the non-specific NOS inhibitor Nω-nitro-L-arginine methyl ester (L-NAME, 1 mM) or PBS for 30 min at room temperature prior to incubation with a superoxide specific dye dihydroethidium (DHE, 3 µM, Molecular Probes, Eugene OR) for 30 minutes at room temperature. After washing twice with PBS, tissues were lightly fixed in 2% paraformaldehyde and mounted with Prolong gold antifade (Invitrogen, Calsbad CA). Multiple images per section were acquired using a Zeiss 710 laser scanning confocal microscope. Fluorescence intensity per nucleus was calculated using Image J analysis software (NIH, Bethesda MD). NOS dependent superoxide was calculated by the difference in fluorescence intensity between sections incubated in PBS and those incubated with L-NAME.
Determination of NO and ONOO−
NO levels were determined colorimetrically after mixing 0.5 ml isolated cardiomyocyte cell lysates and Griess reagent [0.1% N-(1-naphthyl)ethylenediamine in water and 1% sulfanilamide in 5% phosphoric acid]. Concentrations of nitrite were estimated by comparing absorbance readings at 550 nm against standard solutions of NaNO2. NO2-free H2O was used as negative control [21]. Nitrotyrosine content, a footprint of in vivo ONOO− formation, was determined in myocardial tissues using ELISA. Myocardial tissue was homogenized in ice-cold PBS (1/10 w/v) using a PRO 200 homogenizer followed by sonication with a dismembrator (Fisher Scientific, Pittsburgh, PA). Homogenates were centrifuged for 10 min at 12,500 × g at 4°C. Supernatants were collected and samples (50 µg protein) were applied to disposable sterile enzyme-linked immunosorbent assay plates (Corning Glassworks, Corning, NY) prior to overnight incubation at 4°C. The plate was then washed with 200 µl of PBS/0.1% Tween buffer, followed by incubation with heat-inactivated 10% goat serum in PBS for 1 hr at 37°C to block nonspecific binding. The primary antibody (mouse monoclonal antibody against nitrotyrosine from Alexis Biochemicals, San Diego, CA; 1:2000) and secondary antibody (horseradish peroxidase-conjugated anti-mouse IgG, 1:2000) were added, and the peroxidase reaction product was generated using 2.2 mM O-phenylenediamine dihydrochloride solution (Abbott Diagnostics, Abbott Park, IL). Plates were incubated for 20 min in the dark at room temperature and reaction was stopped by addition of 50 µl of 1 N HCl. Optical density was measured at 450 nm with a Spectra Max 190 Microplate Spectrophotometer (Molecular Devices, Sunnyvale, CA) [22].
Western blot analysis
Heart tissue was homogenized in a RIPA lysis buffer and centrifuged at 4°C for 20 min at 12,000xg. Supernatants were removed and protein concentration was measured using the Bradford assay. Samples of equivalent protein concentrations were separated on a 7%, 10%, or 15% SDS-PAGE gel in a mini gel apparatus (Mini-PROTEAN II, Bio-Rad). Membranes were blocked with 5% milk in TBS-Tween20 and incubated in anti-pCaMKII (Thr286), anti-CaMKII, anti-GAPDH, anti-α-tubulin (Cell Signaling Technology, Beverly, MA), anti-OxCaMKII (Met281–282) (Millipore, Billerica MA), anti-phospholamban (PLB, Abcam, Cambridge MA), anti-phosphorylated PLB (Ser16) (Upstate, Lake Placid NY), and anti-SERCA2a (Pierce, Rockford, IL) antibodies overnight at 4°C. Membranes were rinsed and incubated with horseradish peroxidase (HRP) conjugated secondary antibodies and exposed using enzymatic chemiluminescence.
Statistical analysis
Data were presented as mean ± SEM. The one-way ANOVA followed by a Tukey’s post hoc analysis was used to determine statistical significance in most cases. A two-way ANOVA was employed to determine significance for glucose tolerance curve and a two tailed student’s t-test was used for comparison of glucose tolerance AUC.
RESULTS
Effect of sucrose feeding on biometric parameters, glucose tolerance and heart function
Glucose tolerance test was used to confirm insulin resistance and echocardiography was used to determine cardiac dysfunction after 8 weeks of sucrose feeding. Glucose tolerance test showed that sucrose fed mice exhibited around a 2-fold increase in blood glucose levels at 30, 60, and 120 min after IPGTT challenge. Analysis of the area under the curve (AUC) showed that sucrose fed mice exhibit a significant increase compared to control (Fig. S1). Echocardiographic analysis revealed that sucrose diet feeding suppressed fractional shortening confirming the existence of cardiac dysfunction (Fig. 1). Once insulin resistance and cardiac dysfunction were confirmed, mice were given folic acid in drinking water for 4 more weeks. Biometric analysis revealed that neither sucrose feeding nor folic acid, or a combination of the two, exhibited any effect on organ weights (Table 1). Echocardiographic analysis shows a progressive decrease in cardiac performance after 12 weeks of sucrose feeding compared with that at 8 weeks. Interestingly, folic acid not only prevented progression of this cardiac pathological change but also completely reversed depressed fractional shortening which was present at 8 weeks (Fig. 1).
Table 1.
Control | Sucrose | Folic Acid | Sucrose-Folic Acid | |
---|---|---|---|---|
Body Weight (g) | 30.0 ± 0.9 | 28.1 ± 1.9 | 31.2 ± 1.8 | 27.6 ± 0.9 |
Heart Weight (mg) | 162 ± 13 | 152 ± 14 | 169 ± 11 | 137 ± 2 |
HW/TL (mg/mm) | 8.7 ± 0.6 | 8.1 ± 0.6 | 9.2 ± 0.6 | 7.4 ± 0.1 |
Liver Weight (g) | 1.77 ± 0.08 | 1.54 ± 0.13 | 1.67 ± 0.11 | 1.48 ± 0.08 |
LW/TL (g/mm) | 0.095 ± 0.003 | 0.082 ± 0.006 | 0.091 ± 0.006 | 0.080 ± 0.004 |
Kidney Weight (mg) | 475 ± 11 | 471 ± 46 | 497 ± 12 | 412 ± 18 |
KW/TL (mg/mm) | 25.6 ± 1.0 | 25.1 ± 2.1 | 27.0 ± 0.6 | 22.2 ± 1.1 |
Tibia Length (mm) | 18.6 ± 0.5 | 18.7 ± 0.3 | 18.4 ± 0.1 | 18.6 ± 0.4 |
HW = heart weight; LW = liver weight; KW = kidney weight; TL = tibial length, Mean ± SEM, n = 4–5 mice per group, p > 0.05 among any groups.
Effect of folic acid on insulin resistance-induced cardiomyocyte dysfunction
Analysis of cardiomyocytes revealed insulin resistance induced a significant decrease in cell length, peak shortening (PS), and velocities of shortening and relengthening (± dL/dt). Treatment with folic acid was sufficient to restore PS and ± dL/dt back to control levels without affecting the decrease in cell size (Fig. 2). Intracellular Ca2+ transient analysis showed that insulin resistance induced a significant decrease in intracellular Ca2+ rise (ΔFFI) while prolonging Ca2+ clearance. Folic acid was sufficient to restore intracellular Ca2+ rise and Ca2+ clearance rate back to control levels (Fig. 3).
Effect of folic acid on insulin resistance-induced superoxide production, NOS uncoupling, NO and ONOO− generation
Excessive superoxide production leads to deleterious effects on heart function. To this end, levels of superoxide were monitored in cardiac tissue sections to examine NOS uncoupling as a possible source for superoxide. Our data revealed that insulin resistance triggered a significant increase in superoxide levels as indicated by enhanced nuclear DHE fluorescence. To determine if NOS uncoupling contributed to enhanced superoxide production, sections were incubated with L-NAME prior to DHE staining. Our data depicted that the ncreased fluorescence under insulin resistance was restored to control levels when incubated with L-NAME. L-NAME had no significant effect itself. Consistent with increased levels of superoxide (total and L-NAME-dependent), cardiomyocyte NO levels and myocardial ONOO-content (as measured by nitrotyrosine formation) were significantly decreased and increased, respectively, in insulin resistance. Although folic acid did not affect levels of superoxide (total and L-NAME-dependent), NO and ONOO-by itself, it abrogated insulin resistance-induced changes in superoxide, NO and ONOO− (Fig. 4).
Insulin resistance induced changes in RYR2
To examine the effect insulin resistance on myocardial intracellular Ca2+ cycling, we examined intracellular Ca2+ leak from the RYR2 Ca2+ channel. Cardiomyocytes from insulin resistant mice exhibited an increase in tetracaine-sensitive intracellular Ca2+ rise, indicating the nature of RYR as an origin for Ca2+ release. Interestingly, cardiomyocytes from insulin resistant mice receiving folic acid displayed a much smaller RYR2-dependent intracellular Ca2+ rise resembling the magnitude of control group. Such rise in intracellular Ca2+ under insulin resistance was associated with spontaneous Ca2+ spikes in insulin resistance group, the effect of which was abolished by folic acid. These findings suggest that RYR2 leak may trigger spontaneous Ca2+ spikes under insulin resistance state while such effect may be ameliorated by folic acid treatment (Fig. 5).
Assessment of Ca2+ handling proteins
To further elucidate the possible role of RYR2 in insulin resistance and/or folic acid-induced myocardial changes, phosphorylation and oxidation of CaMKII were evaluated. Insulin resistance led to an increase in CaMKII phosphorylation, the effect of which was ablated by folic acid. Folic acid itself did not exhibit any effect on CaMKII phosphorylation. Neither insulin resistance nor folic acid exerted any notable effect on oxidation of CaMKII. In addition, neither insulin resistance nor folic acid, or both, affected levels of intracellular Ca2+ regulatory proteins SERCA2a and the SERCA inhibitory phospholamban (pan or phosphorylated) (Fig. 6).
DISCUSSION
The salient data from our present study reveal that insulin resistance using sucrose feeding induces cardiac mechanical defect including echocardiographic, cardiomyocyte contractile, and intracellular Ca2+ handling aberrations. In this study, insulin resistance was induced in mice after they reached adulthood, similar to our previous report [23], to mimic the clinical presentations of insulin resistance in adults. In accordance with cardiac mechanical dysfunction, NOS uncoupling was obvious under insulin resistance (decreased NO levels, elevated production of superoxide and ONOO−) along with Ca2+ leak from ryanodine receptor. NOS recoupling with folic acid restored NO levels, cardiac contractile and intracellular Ca2+ properties as well as suppressed increased levels of superoxide and ONOO− under insulin resistance. Our data further revealed that insulin resistance promoted CaMKII phosphorylation, the effect of which may be reversed by folic acid. Interestingly, despite the increased superoxide production, little change was noted for the oxidation state of CaMKII. Our findings favored that notion that cardiac dysfunction may be originated from increased Ca2+ leak from RYR through CaMKII phosphorylation, which may promote NOS uncoupling in insulin resistance, the effects of which may be alleviated or mitigated by NOS uncoupling using folic acid administration.
Presence of oxidative stress has been well documented in insulin resistance to contribute to detrimental myocardial sequelae [3, 24, 25]. In spite of the rather significant role of ROS in insulin resistance and metabolic syndrome, clinical trials using antioxidants for the management of cardiac diseases have had mixed outcomes, suggesting that targeting ROS producing enzymes may be a better therapeutic option [26]. For example, inhibition of NADPH oxidase (NOX) may prevent NOS uncoupling suggesting a downstream role of NOS uncoupling in NOX-associated ROS production [27]. Interestingly, damage to mitochondria by oxidative stress causes increased production of superoxide from the damaged mitochondria themselves [28]. Data from our study showed that hearts from insulin resistant mice displayed increased superoxide production. Oxidative stress has been demonstrated to trigger NOS uncoupling rending NOS to produce O2− rather than NO [4–6]. This is supported by our current observation of decrease in NO, elevated superoxide and ONOO− levels under insulin resistance. Four week of folic acid treatment, which is known to recouple NOS [7–9], effectively eliminated NOS-dependent superoxide, restored NO production, suppressed nitrotyrosine formation (depicting ONOO− levels) and reversed cardiac mechanical dysfunction under insulin resistance, indicating a possible role of NOS recoupling in folic acid-induced beneficial cardiac effect. Although other sources of ROS may exist in our current experimental setting, these data favor that the role of uncoupled NOS as a candidate generator of ROS and subsequently myocardial dysfunction.
Cardiovascular complications in diabetes and insulin resistance often manifest as decreased fractional shortening and impaired cardiomyocyte function [21, 23, 27]. In this study, 8 weeks of sucrose feeding led to a state of insulin resistance and decreased fractional shortening, which were worsened after 12 weeks of sucrose feeding. Due to the contributions of ROS to insulin resistance and the uncoupled state of NOS, we hypothesized that recoupling of NOS may be sufficient to reverse cardiac dysfunction in insulin resistance. With the exception of resting cell length, administration of folic acid restored cardiomyocyte mechanical anomalies and fractional shortening under insulin resistance, supporting a role of NOS uncoupling in insulin resistance-induced cardiac contractile and intracellular Ca2+ derangement. Our study noted reduced resting cell length following sucrose feeding length, consistent with the notion of cardiomyocyte atrophy under insulin resistance [29]. It has been suggested that cardiomyocyte atrophy may occur from a loss of insulin/insulin-like growth factor 1 signaling and an increased atrogen-1 expression [30].
It is well conceived that defects in intracellular Ca2+ cycling may underscore myocardial contractile dysfunction in insulin resistance [23]. In our hands, high sucrose feeding induced a decreased ΔFFI and prolonged intracellular Ca2+ decay rate. Reversal of NOS uncoupling using folic acid restored these parameters to near control levels. Several mechanisms may contribute to the aberrant intracellular Ca2+ handling under insulin resistance including redox modification of essential contractile or intracellular Ca2+ regulatory proteins [31, 32]. In particular, ryanodine receptor is sensitive to redox activation as well as phosphorylation by CaMKII, both of which alter ryanodine function. Given that impaired RYR2 function has been documented in diabetic heart complications [33], RYR2 Ca2+ leak was evaluated in this study. Analysis of tetracaine-dependent resting intracellular Ca2+ rise revealed that insulin resistance displays a significant Ca2+ leak through the RYR receptor to trigger spontaneous cardiomyocyte contraction.
To better understand intracellular Ca2+ cycling defects under insulin resistance, other proteins essential for intracellular Ca2+ homeostasis were evaluated including SERCA2a, phospholamban and CaMKII given the pivotal roles of these proteins in intracellular Ca2+ handling [13]. CaMKII is considered a master regulator for intracellular Ca2+ cycling through its phosphorylation of RYR and phospholamban to govern their respective activity [34]. Considering defective RYR channel function observed in our study, it is plausible to speculate the role of CaMKII as a likely target for NOS uncoupling in insulin resistance. Both oxidation and phosphorylation of CaMKII were evaluated as both play a key role in its enzymatic activation [35]. Interestingly, little effect was noted in oxidation of CaMKII somewhat inconsistent with enhanced superoxide production following sucrose feeding. To the contrary, phosphorylation of CaMKII was increased under insulin resistance, the effect of which was reversed by folic acid. These data strongly suggest that CaMKII is a directly downstream target for NOS uncoupling to underlie cardiac contractile dysfunction in insulin resistance.
In summary, our findings indicated that NOS uncoupling may be the underlying mechanism responsible for cardiac dysfunction in insulin resistance. Our data revealed that insulin resistance promoted NOS uncoupling leading to echocardiographic and cardiomyocyte abnormalities in conjunction with intracellular Ca2+ dysregulation. Underlying this contractile dysfunction is impaired function of the RYR Ca2+ channel leading to resting Ca2+ leak, which can be attributed to phosphorylation of CaMKII. Perhaps the most significant finding from our study is that the common dietary supplement folic acid effectively restores proper NOS function and eliminates cardiac abnormalities under insulin resistance, suggesting the therapeutic promises of NOS recoupling in insulin resistance-induced cardiac anomalies. The beneficial effect of folic acid on cardiac anomalies in insulin resistance is consistent with that offered by the antioxidant metallothionein and catalase [23, 36], which are known to alleviate oxidative stress and preserve NOS coupling [6].
Supplementary Material
Research highlights.
We examined the effect of folic acid on insulin resistance-induced heart dysfunction;
Folic acid rescues against insulin resistance-induced cardiac dysfunction;
The beneficial effect of folic acid was related to improved intracellular Ca2+ handling;
ACKNOWLEDGMENTS
This work was supported in part by the NIH P20 GM134012.
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
DISCLOSURES: None
BIBLIOGRAPHY
- 1.Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, Bravata DM, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Magid D, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Nichol G, Paynter NP, Schreiner PJ, Sorlie PD, Stein J, Turan TN, Virani SS, Wong ND, Woo D, Turner MB American Heart Association Statistics, C; Stroke Statistics, S. Executive summary: heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:143–152. doi: 10.1161/CIR.0b013e318282ab8f. [DOI] [PubMed] [Google Scholar]
- 2.Mellor KM, Ritchie RH, Delbridge LM. Reactive oxygen species and insulin-resistant cardiomyopathy. Clin Exp Pharmacol Physiol. 2010;37:222–228. doi: 10.1111/j.1440-1681.2009.05274.x. [DOI] [PubMed] [Google Scholar]
- 3.Tsutsui H, Kinugawa S, Matsushima S. Oxidative stress and heart failure. Am J Physiol Heart Circ Physiol. 2011;301:H2181–H2190. doi: 10.1152/ajpheart.00554.2011. [DOI] [PubMed] [Google Scholar]
- 4.Roe ND, Ren J. Nitric oxide synthase uncoupling: A therapeutic target in cardiovascular diseases. Vascul Pharmacol. 2012 doi: 10.1016/j.vph.2012.02.004. [DOI] [PubMed] [Google Scholar]
- 5.Moens AL, Takimoto E, Tocchetti CG, Chakir K, Bedja D, Cormaci G, Ketner EA, Majmudar M, Gabrielson K, Halushka MK, Mitchell JB, Biswal S, Channon KM, Wolin MS, Alp NJ, Paolocci N, Champion HC, Kass DA. Reversal of cardiac hypertrophy and fibrosis from pressure overload by tetrahydrobiopterin: efficacy of recoupling nitric oxide synthase as a therapeutic strategy. Circulation. 2008;117:2626–2636. doi: 10.1161/CIRCULATIONAHA.107.737031. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Ceylan-Isik AF, Guo KK, Carlson EC, Privratsky JR, Liao SJ, Cai L, Chen AF, Ren J. Metallothionein abrogates GTP cyclohydrolase I inhibition-induced cardiac contractile and morphological defects: role of mitochondrial biogenesis. Hypertension. 2009;53:1023–1031. doi: 10.1161/HYPERTENSIONAHA.108.123422. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Moens AL, Champion HC, Claeys MJ, Tavazzi B, Kaminski PM, Wolin MS, Borgonjon DJ, Van Nassauw L, Haile A, Zviman M, Bedja D, Wuyts FL, Elsaesser RS, Cos P, Gabrielson KL, Lazzarino G, Paolocci N, Timmermans JP, Vrints CJ, Kass DA. High-dose folic acid pretreatment blunts cardiac dysfunction during ischemia coupled to maintenance of high-energy phosphates and reduces postreperfusion injury. Circulation. 2008;117:1810–1819. doi: 10.1161/CIRCULATIONAHA.107.725481. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Gao L, Siu KL, Chalupsky K, Nguyen A, Chen P, Weintraub NL, Galis Z, Cai H. Role of uncoupled endothelial nitric oxide synthase in abdominal aortic aneurysm formation: treatment with folic acid. Hypertension. 2012;59:158–166. doi: 10.1161/HYPERTENSIONAHA.111.181644. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Gao L, Chalupsky K, Stefani E, Cai H. Mechanistic insights into folic aciddependent vascular protection: dihydrofolate reductase (DHFR)-mediated reduction in oxidant stress in endothelial cells and angiotensin II-infused mice: a novel HPLC-based fluorescent assay for DHFR activity. J Mol Cell Cardiol. 2009;47:752–760. doi: 10.1016/j.yjmcc.2009.07.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Mishra PK, Givvimani S, Metreveli N, Tyagi SC. Attenuation of beta2-adrenergic receptors and homocysteine metabolic enzymes cause diabetic cardiomyopathy. Biochem Biophys Res Commun. 2010;401:175–181. doi: 10.1016/j.bbrc.2010.09.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Kolling J, Scherer EB, da Cunha AA, da Cunha MJ, Wyse AT. Homocysteine induces oxidative-nitrative stress in heart of rats: prevention by folic acid. Cardiovasc Toxicol. 2011;11:67–73. doi: 10.1007/s12012-010-9094-7. [DOI] [PubMed] [Google Scholar]
- 12.Moens AL, Vrints CJ, Claeys MJ, Timmermans JP, Champion HC, Kass DA. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. Am J Physiol Heart Circ Physiol. 2008;294:H1971–H1977. doi: 10.1152/ajpheart.91503.2007. [DOI] [PubMed] [Google Scholar]
- 13.Hadri L, Hajjar RJ. Calcium cycling proteins and their association with heart failure. Clin Pharmacol Ther. 2011;90:620–624. doi: 10.1038/clpt.2011.161. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Ochi R, Gupte SA. Ryanodine receptor: a novel therapeutic target in heart disease. Recent Pat Cardiovasc Drug Discov. 2007;2:110–118. doi: 10.2174/157489007780832524. [DOI] [PubMed] [Google Scholar]
- 15.Currie S, Elliott EB, Smith GL, Loughrey CM. Two candidates at the heart of dysfunction: The ryanodine receptor and calcium/calmodulin protein kinase II as potential targets for therapeutic intervention-An in vivo perspective. Pharmacol Ther. 2011;131:204–220. doi: 10.1016/j.pharmthera.2011.02.006. [DOI] [PubMed] [Google Scholar]
- 16.Shao CH, Wehrens XH, Wyatt TA, Parbhu S, Rozanski GJ, Patel KP, Bidasee KR. Exercise training during diabetes attenuates cardiac ryanodine receptor dysregulation. J Appl Physiol. 2009;106:1280–1292. doi: 10.1152/japplphysiol.91280.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Alkaitis MS, Crabtree MJ. Recoupling the cardiac nitric oxide synthases: tetrahydrobiopterin synthesis and recycling. Current heart failure reports. 2012;9:200–210. doi: 10.1007/s11897-012-0097-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Dong F, Kandadi MR, Ren J, Sreejayan N. Chromium (D-phenylalanine)3 supplementation alters glucose disposal, insulin signaling, and glucose transporter-4 membrane translocation in insulin-resistant mice. J Nutr. 2008;138:1846–1851. doi: 10.1093/jn/138.10.1846. [DOI] [PubMed] [Google Scholar]
- 19.Shannon TR, Ginsburg KS, Bers DM. Quantitative assessment of the SR Ca2+ leak-load relationship. Circ Res. 2002;91:594–600. doi: 10.1161/01.res.0000036914.12686.28. [DOI] [PubMed] [Google Scholar]
- 20.Gonzalez DR, Treuer AV, Castellanos J, Dulce RA, Hare JM. Impaired S-nitrosylation of the ryanodine receptor caused by xanthine oxidase activity contributes to calcium leak in heart failure. J Biol Chem. 2010;285:28938–28945. doi: 10.1074/jbc.M110.154948. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Ren J, Duan J, Thomas DP, Yang X, Sreejayan N, Sowers JR, Leri A, Kajstura J, Gao F, Anversa P. IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction. American journal of physiology. Regulatory, integrative and comparative physiology. 2008;294:R793–R802. doi: 10.1152/ajpregu.00713.2007. [DOI] [PubMed] [Google Scholar]
- 22.Dong F, Zhang X, Culver B, Chew HG, Jr, Kelley RO, Ren J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release: involvement of nitric oxide synthase and protein tyrosine nitration. Clin Sci (Lond) 2005;109:277–286. doi: 10.1042/CS20040278. [DOI] [PubMed] [Google Scholar]
- 23.Dong F, Fang CX, Yang X, Zhang X, Lopez FL, Ren J. Cardiac overexpression of catalase rescues cardiac contractile dysfunction induced by insulin resistance: Role of oxidative stress, protein carbonyl formation and insulin sensitivity. Diabetologia. 2006;49:1421–1433. doi: 10.1007/s00125-006-0230-7. [DOI] [PubMed] [Google Scholar]
- 24.Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107:1058–1070. doi: 10.1161/CIRCRESAHA.110.223545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Murarka S, Movahed MR. Diabetic cardiomyopathy. J Card Fail. 2010;16:971–979. doi: 10.1016/j.cardfail.2010.07.249. [DOI] [PubMed] [Google Scholar]
- 26.Sheikh-Ali M, Chehade JM, Mooradian AD. The antioxidant paradox in diabetes mellitus. Am J Ther. 2011;18:266–278. doi: 10.1097/MJT.0b013e3181b7badf. [DOI] [PubMed] [Google Scholar]
- 27.Roe ND, Thomas DP, Ren J. Inhibition of NADPH oxidase alleviates experimental diabetes-induced myocardial contractile dysfunction. Diabetes Obes Metab. 2011;13:465–473. doi: 10.1111/j.1463-1326.2011.01369.x. [DOI] [PubMed] [Google Scholar]
- 28.Van Remmen H, Richardson A. Oxidative damage to mitochondria and aging. Exp Gerontol. 2001;36:957–968. doi: 10.1016/s0531-5565(01)00093-6. [DOI] [PubMed] [Google Scholar]
- 29.Roe ND, Ren J. Akt2 knockout mitigates chronic iNOS inhibition-induced cardiomyocyte atrophy and contractile dysfunction despite persistent insulin resistance. Toxicol Lett. 2011;207:222–231. doi: 10.1016/j.toxlet.2011.09.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Wang H, Liu D, Cao P, Lecker S, Hu Z. Atrogin-1 affects muscle protein synthesis and degradation when energy metabolism is impaired by the antidiabetes drug berberine. Diabetes. 2010;59:1879–1889. doi: 10.2337/db10-0207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Bogeski I, Kappl R, Kummerow C, Gulaboski R, Hoth M, Niemeyer BA. Redox regulation of calcium ion channels: chemical and physiological aspects. Cell Calcium. 2011;50:407–423. doi: 10.1016/j.ceca.2011.07.006. [DOI] [PubMed] [Google Scholar]
- 32.Sumandea MP, Steinberg SF. Redox signaling and cardiac sarcomeres. J Biol Chem. 2011;286:9921–9927. doi: 10.1074/jbc.R110.175489. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Turan B, Vassort G. Ryanodine receptor: a new therapeutic target to control diabetic cardiomyopathy. Antioxid Redox Signal. 2011;15:1847–1861. doi: 10.1089/ars.2010.3725. [DOI] [PubMed] [Google Scholar]
- 34.Anderson ME, Brown JH, Bers DM. CaMKII in myocardial hypertrophy and heart failure. J Mol Cell Cardiol. 2011;51:468–473. doi: 10.1016/j.yjmcc.2011.01.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Erickson JR, He BJ, Grumbach IM, Anderson ME. CaMKII in the cardiovascular system: sensing redox states. Physiol Rev. 2011;91:889–915. doi: 10.1152/physrev.00018.2010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Fang CX, Dong F, Ren BH, Epstein PN, Ren J. Metallothionein alleviates cardiac contractile dysfunction induced by insulin resistance: role of Akt phosphorylation, PTB1B, PPARgamma and c-Jun. Diabetologia. 2005;48:2412–2421. doi: 10.1007/s00125-005-1940-y. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.